Takeaway

• The US Food and Drug Administration (FDA) has approved the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel) for the treatment of patients with refractory/relapsed multiple myeloma (R/R MM) who have previously received ≥ 4 therapies.

Why this matters

• Cilta-cel is a novel CAR T-cell therapy targeting the...